

# Development of HIT compounds of MLKL inhibitors for treatment of nonalcoholic fatty liver disease

Hanyang University



METABOLIC	Hit
Product Type	Chemical product
Indication	Non-alcoholic fatty liver disease (NAFLD)
Target	MLKL
MoA(Mechanism of Action)	Inhibition of necroptosis (Inhibition of MLKL oligomerization)
Competitiveness	The world's first MLKL necroptosis inhibitor
Development Stage	Hit
Route of Administration	Oral